MedPath

Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Registration Number
NCT01960179
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks in patients with type 2 diabetes in Japan

Secondary Objective:

To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks on:

* HbA1c (Glycated hemoglobin A1c) reduction;

* Fasting plasma glucose;

* Body weight.

Detailed Description

* Group 1: 60 weeks ± 11 days

* Group 2: 32 weeks ± 7 days

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
361
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lixisenatidelixisenatide AVE0010lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
Primary Outcome Measures
NameTimeMethod
Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.from baseline to 24 weeks and 52 weeks
Secondary Outcome Measures
NameTimeMethod
Absolute change in HbA1cfrom baseline to week 24 and week 52
Absolute change in body weightfrom baseline to week 24 and week 52
Absolute change in fasting plasma glucosefrom baseline to week 24 and week 52

Trial Locations

Locations (30)

Investigational Site Number 392006

🇯🇵

Adachi-Ku, Japan

Investigational Site Number 392005

🇯🇵

Chiba-Shi, Japan

Investigational Site Number 392010

🇯🇵

Chiyoda-Ku, Japan

Investigational Site Number 392004

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392015

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392003

🇯🇵

Chuoh-Ku, Japan

Investigational Site Number 392012

🇯🇵

Ebina-Shi, Japan

Investigational Site Number 392024

🇯🇵

Higashiosaka-Shi, Japan

Investigational Site Number 392023

🇯🇵

Kashiwara-Shi, Japan

Investigational Site Number 392008

🇯🇵

Kawagoe-Shi, Japan

Scroll for more (20 remaining)
Investigational Site Number 392006
🇯🇵Adachi-Ku, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.